Print

AVEG 031

A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 gag-pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramusculary by Needle and Syringe or Biojector 2000 Needle-free Jet Injection System in HIV-1 Uninfected Adult Volunteers

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) July 16, 1997
APL 400-047,ALVAC-HIV MN120TMG strain (vCP205) Canarypox Env gp120, TM gp41, gag, protease B MN/LAI; Protein env, rev
APL 400-047 DNA
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
USA 40
NCT00001088
http://www.clinicaltrials.gov/ct2/show/NCT00001088